<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00226122</url>
  </required_header>
  <id_info>
    <org_study_id>INDO181202</org_study_id>
    <secondary_id>01</secondary_id>
    <nct_id>NCT00226122</nct_id>
  </id_info>
  <brief_title>The Effect of Indomethacin in Monosymptomatic Enuresis Nocturnal</brief_title>
  <official_title>The Effect of Indomethacin in Monosymptomatic Enuresis Nocturnal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Monosymptomatic nocturnal enuresis, defined as the involuntary loss of urine during the night&#xD;
      at an age where voluntary bladder control should have been attained and on the background of&#xD;
      normal urinary tract function, is a rather common disease of childhood with an estimated&#xD;
      prevalence of 5-10% at tha age of 7 and a spontaneous remission rate of 15% per year.&#xD;
&#xD;
      The present study consists of two phases; an in-patient phase and an ambulatory phase.&#xD;
&#xD;
      In the in-patient phase we will examine the regulation of sodium and the circadian rhythm of&#xD;
      the hormones that affect this regulation in children with enuresis nocturnal and healthy&#xD;
      children, as well as the impact of indomethacin on renal water and electrolyte excretion.&#xD;
&#xD;
      In the ambulatory phase we will examine the efficacy and safety of a treatment modality&#xD;
      consisting of a combination of dDAVP and indomethacin in patients with severe enuresis where&#xD;
      dDAVP as monotherapy is inadequate.&#xD;
&#xD;
      A significant number of children with enuresis and nocturnal polyuria do not respond to&#xD;
      treatment with dDAVP. If a combination treatment with dDAVP and indomethacin proves superior&#xD;
      to dDAVP alone the regimen could readily be used in those difficult to cure cases of&#xD;
      enuresis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The &quot;in-patient&quot; phase is a comparative circadian study of three groups of participants and a&#xD;
      non-placebo controlled study of the renal effects of indomethacin with special reference the&#xD;
      renal handling of sodium.&#xD;
&#xD;
      The ambulatory phase is designed as a randomized double blind, crossover placebo controlled&#xD;
      for indomethacin study of the efficacy and safety of a combination treatment with&#xD;
      indomethacin and dDAVP.&#xD;
&#xD;
      In-patient phase: Primary effect parameters will be the diuresis, urinary osmolality, sodium&#xD;
      excretion prior to and after the administration of indomethacin.&#xD;
&#xD;
      Secondary effect parameters will be the following: GFR, K+ excretion, creatinine excretion,&#xD;
      urea excretion, as well as urinary concentrations of aquaporin 2 (AQP2), PGE2, AVP, URO,&#xD;
      Na-transporter protein, concentration of renin, ANG II, ALDO, ANP, in plasma, prior to and&#xD;
      after the administration of indomethacin.&#xD;
&#xD;
      Ambulatory phase: Primary effect parameter will be the number of dry nights achieved in the&#xD;
      two treatment periods. Secondary effect parameters will be the nocturnal urine production,&#xD;
      and the enuresis volumes In-patient phase: Day-night ratios will be calculated for all&#xD;
      parameters tested. The circadian rhythm of hormones blood pressure and electrolyte excretion&#xD;
      will be analyzed using COSINOR analysis.&#xD;
&#xD;
      The effect of indomethacin on the parameters tested will be compared to the basal&#xD;
      measurements using student's t-test, ANOVA for repeated measurements or non-parametric tests.&#xD;
      All statistical inference will take place on a &quot;protocol population&quot; basis.&#xD;
&#xD;
      Ambulatory phase: The efficacy of the combination treatment will be tested against placebo&#xD;
      (only for indomethacin) with help of student's t-test, x2 test or non-parametric tests.&#xD;
&#xD;
      The results from the home recordings will be compared for the two treatment periods using&#xD;
      non-parametric tests. The effect parameters that will undergo statistical analysis are the&#xD;
      number of wet nights, the enuresis volume and the nocturnal urine production. The analysis&#xD;
      will be on the basis of intention to treat population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Enuresis episodes</measure>
    <time_frame>3 and 7 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine production, electrolyte excretion, hormonal changes</measure>
    <time_frame>3 and 7 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">56</enrollment>
  <condition>Enuresis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>Indomethacin capsules 50 mg</description>
    <other_name>Confortid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Monosymptomatic enuresis nocturnal&#xD;
&#xD;
          -  At least 3 nights with enuresis per week&#xD;
&#xD;
          -  Incomplete response to dDAVP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Daytime incontinence&#xD;
&#xD;
          -  Urgency&#xD;
&#xD;
          -  Frequency&#xD;
&#xD;
          -  Other conditions that influence normal urine production&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konstantinos Kamperis, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Institute, University of Aarhus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept of Pediatrics, Aarhus University Hospital</name>
      <address>
        <city>Aarhus N</city>
        <state>Jutland</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>September 23, 2005</study_first_submitted>
  <study_first_submitted_qc>September 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2005</study_first_posted>
  <last_update_submitted>June 24, 2010</last_update_submitted>
  <last_update_submitted_qc>June 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Konstantinos Kamperis MD PhD</name_title>
    <organization>Pediatric Research Laboratory, Aarhus University Hospital Skejby Aarhus Denmark</organization>
  </responsible_party>
  <keyword>Enuresis</keyword>
  <keyword>Nocturnal</keyword>
  <keyword>Monosymptomatic</keyword>
  <keyword>DDAVP</keyword>
  <keyword>Indomethacin</keyword>
  <keyword>Randomized</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Nocturnal Enuresis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

